Biological terrorism: Understanding the threat, preparation, and medical response

Disease-a-Month

Volumn 46, Issue 2, 2000, Pages 127-190

  Franz, David R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v}  

^a US Army Medical Research   (United States)

^b US Army Med Res Inst Infect Dis   (United States)

^c U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^d UNITED NATIONS   (United States)

^e Trilateral Experts' Committee   (United States)

^f Textbook Mil Med Chem Biol Def   (United States)

^g NATIONAL ACADEMY OF SCIENCES   (United States)

^h US Dept Justice's Ctr Dom P   (United States)

ⁱ SOUTHERN RESEARCH INSTITUTE   (United States)

^j KANSAS STATE UNIVERSITY   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

^m Task Force Aesculapius   (United States)

ⁿ Army Medical Department Center and School   (United States)

^o BROOKE ARMY MEDICAL CENTER   (United States)

^p Brooke Army Medical Center ^*  (United States)

^q WALTER REED ARMY MEDICAL CENTER   (United States)

^r UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^s RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^t Russian Military Academy of Medicine   (Russian Federation)

^u RUSH UNIVERSITY MEDICAL CENTER   (United States)

^v Adv Technol and Intl Health   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTHRAX VACCINE; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BOTULINUM ANTISERUM; BOTULINUM TOXIN; BRUCELLA VACCINE; CHEMICAL AGENT; CHLORAMPHENICOL; CIDOFOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; Q FEVER VACCINE; RIBAVIRIN; RICIN; RIFAMPICIN; SMALLPOX VACCINE; STAPHYLOCOCCUS ENTEROTOXIN; STREPTOMYCIN; TETRACYCLINE; TOXIN; TRIPLE VACCINE; TULAREMIA VACCINE; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS ANTIBODY;

ANTHRAX; BIOLOGICAL WARFARE; BIOTECHNOLOGY; BRUCELLOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; HUMAN; INCUBATION TIME; INTOXICATION; PLAGUE; POLITICS; Q FEVER; REVIEW; SMALLPOX; SYMPTOMATOLOGY; TOXICOKINETICS; TULAREMIA; VACCINATION; VIRUS ENCEPHALITIS; VIRUS HEMORRHAGIC FEVER; ARTICLE; COMMUNICABLE DISEASE; EPIDEMIC; FORGERY; UNITED STATES; VIOLENCE;

BIOLOGICAL WARFARE; COMMUNICABLE DISEASES; DISEASE OUTBREAKS; FRAUD; HUMANS; TOXINS, BIOLOGICAL; UNITED STATES; VIOLENCE;

EID: 0034134083     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(00)90017-8     Document Type: Review

References (56)

1. United States Department of State. Report of the United States of America to the United Nations Department of Disarmament Affairs. Washington (DC): US Department of State; 1998.
2. Williams P, Wallace D. Unit 731: Japan's secret biological warfare in World War II. New York: The Free Press; 1998.
3. Alibek K. Biohazard. New York: Random House; 1999.
4. Zajtchuk R, editor. Medical aspects of chemical and biological warfare. The US biological warfare and biological defense programs. Washington (DC): Borden Institute; 1997.
5. Geissler E. Biological and toxin weapons today. Oxford: Oxford University Press; 1986.
6. Trevan T. Saddam's secrets: the hunt for Iraq's hidden weapons. London: Harper Collins; 1999.
7. Mangold T, Goldberg J. Plague wars: the true story of biological warfare. London: Macmillan; 1999.
8. Ellis JD, Perry T. Nunn-Lugar's unfinished agenda. http://www.armscontrol.org/ ACT/oct97/nunnoct.htm
9. Pomerantsev AP, Staritsin NA, Mockov Yu V, et al. Expression of cereolysin AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 1977;15:1846-50.
10. Broad WJ, Miller J. Once he devised germ weapons, now he defends against them. New York Times 1998 Nov 3;Sect. F:1 (col. 2).
11. Roberts B, editor. Terrorism with chemical and biological weapons. Alexandria (VA): The Chemical and Biological Arms Control Institute; 1997.
12. Carus WS. Bioterrorism and biocrimes: the illicit use of biological agents in the 20th century. Washington (DC): The National Defense University; 1999.
13. Lederberg J, editor. Biological weapons: limiting the threat. Cambridge (MA): The MIT Press; 1999.
14. Horwitz S. FBI sends alert to Jewish group. The Washington Post 1997 Apr 26;Metro Sect: C01.
15. Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999;341:815-26.
16. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-8.
17. Abramova FA, Grinberg LM, Yampolskaya OV, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci USA 1993;90:2291-4.
18. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-43.
19. Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:632-45.
20. Wright GG, Green TW, Kanode RF Jr. Studies on immunity in anthrax: V. immunizing activity of alum-precipitated protective antigen. J Immunol 1954;73:387-91.
21. Grimont F, Verger JM, Cornelis P, et al. Molecular typing of Brucella with cloned DNA probes. Res Microbiol 1992;143:55-65.
22. Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. Rev Infect Dis 1991;13:359-72.
23. Joint FAO/WHO expert committee on brucellosis. World Health Organ Tech Report Ser 1986;740:1-132.
24. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine 1985;64:251-69.
25. Forsman M, Sandstrom G, Jaurin B. Identification of Francisella species and discrimination of type A and type B strains for F tularensis by 16S rRNA analysis. Appl Environmental Microbiol 1990;56:949-55.
26. Saslaw S, Eigelsbach HT, Prior JA, et al. Tularemia vaccine study. I. respiratory challenge. Arch Intern Med 1961;107:134-46.
27. Crook LD, Tempest B. Plague: a clinical review of 27 cases. Arch Intern Med 1992;152:1253-6.
28. Cavanaugh DC, Elisberg BL, Llewellyn CH, et al. Plague immunization. V: indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974; 129(Suppl):S37-40.
29. Smith DL, Ayres JG, Blair I, et al. A large Q fever outbreak in the West Midlands: clinical aspects. Respir Med 1993;87:509-16.
30. Derrick EH. The course of infection with Coxiella burnetii. Med J Aust 1973;1:1051-7.
31. Weisburg WG, Dobson ME, Samuel JE, et al. Phylogenetic diversity of the rickettsias. J Bacteriol 1989;171:4202-6.
32. Peter O, Dupuis D, Bee R, et al. Comparison of enzyme-linked immunosorbent assay for diagnosis of Q fever. J Clin Microbiol 1987;25:1063-7.
33. Brouqui P, Dupont HT, Drancourt M, et al. Chronic Q fever: ninety-two cases from France, including 27 cases without endocarditis. Arch Intern Med 1993;153:642-8.
34. Benenson AS. Q fever vaccine: efficacy and present status. In: Smadel JE, editor. Symposium on Q fever by the Committee on Rickettsial Diseases. Washington (DC): Armed Forces Epidemiology Board; 1959. p. 47-60.
35. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva (Switzerland): World Health Organization; 1998. p. 1341.
36. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull WHO 1970;43:669-79.
37. Ibrahim MS, Esposito JJ, Jahrling, Lofts RS. The potential of 5 nuclease PCR for detecting a single-base polymorphism in orthopoxvirus. Mol Cell Probes 1997;11:143-7.
38. Dixon CW. Smallpox. London: J & A Churchill; 1962.
39. Martin DH, Eddy GA, Sudia WD, et al. An epidemiological study of Venezuelan equine encephalomyelitis in Costa Rica, 1970. Am J Epidemiol 1972;95:2565-78.
40. Weaver SC, Salas R, Rico-Hesse R, et al. Re-emergence of epidemic Venezuelan equine encephalitis in South America. Lancet 1966;348:436-40.
41. Goldfield M, Welsh JN, Taylor BF. The 1959 outbreak of eastern encephalitis in New Jersey. Am J Epidemiiol 1969;87:32-8.
42. Jahrling PB. Filoviruses and arenaviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 6th ed. Washington (DC): ASM Press; 1995. p. 1068-81.
43. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11:S750-61.
44. Wannemacher RW, Wiener SL. Trichothecene mycotoxins. In: Zajtchuck R, editor. Textbook of military medicine: medical aspects of chemical and biological warfare. Washington (DC);Borden Institute; 1997. p. 655-76.
45. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
46. Rauber A, Heard J. Castor bean toxicity re-examined: a new perspective. Vet Hum Toxicol 1985;27:498-502.
47. Fostad O, Kvalheim G, Godal A, et al. Phase I study of the plant protein ricin. Cancer Res 1984;44:862-5.
48. Crompton R, Gall D. Georgi Markov: death in a pellet. Med Leg J 1980;48:51-62.
49. Wilhelmsen C, Pitt L. Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Vet Pathol 1993;30:482.
50. Karsenty E, Shemer J, Alshench I, et al. Medical aspects of the Iraqi missile attacks on Israel. Isr J Med Sci 1991;27:603-7.
51. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Inf Dis 1997;3:83-94.
52. World Health Organization. Health aspects of chemical and biological weapons: report of a WHO group of consultants. Geneva: WHO; 1970.
53. Baumgarrtner HP, Loffler F. The collection performance of electret filters in the particle size range 10 nm-10 mm. J Aerosol Sci 1986;17:438-45.
54. Falkenrath R, Newman R, Thayer B. America's Achilles' heel: nuclear, biological, and chemical terrorism and covert attack. Cambridge (MA): MIT Press; 1998. p. 19-26..
55. Dunn CS, Donaldson AI. Foot-and-mouth disease in Taiwan. Vet Rec 1997;140: 407.
56. Dunn CS. Natural adaptation to pigs of a Taiwanese isolate of foot-and-mouth disease. Vet Rec 1997;141:174-5.